lung disease
In a bid to expand recognition and treatment of alpha-1 antitrypsin deficiency, a cause of COPD, Grifols is making its over-the-counter genetic test available for free.
New publications have expanded the discussion around the Envisia lung disease test as the firm builds evidence for its recently launched lung cancer nasal swab assay.
NASA increasingly believes the platform could be used in the medical arena.
Three Investment Banks Initiate Coverage of Biodesix
William Blair, Canaccord Genuity, and BTIG on Monday initiated coverage of newly public Biodesix, with ratings ranging from Buy to Outperform.
Veracyte Licenses Lung Disease Genomic Classifier From Yale University
Veracyte has obtained rights to a 52-gene signature developed by Yale researchers to predict disease progression in patients with idiopathic pulmonary fibrosis.